Table 3.

Multivariate analysis on NRM considering the interaction between CMV reactivation and the other factors

VariablesBaselineInteraction term
HR95% CIPHR95% CIP
CMV reactivation 1.92 1.05-3.50 .035    
Underlying disease*       
 Acute lymphoblastic leukemia 1.09 0.89-1.32 .41 1.15 0.89-1.47 .29 
 Myelodysplastic syndromes 1.05 0.86-1.29 .64 1.13 0.87-1.46 .36 
 CML 0.74 0.48-1.14 .17 1.76 1.05-2.96 .033 
Patient age ≥ 50 y 1.51 1.26-1.80 <.001 1.11 0.89-1.40 .35 
Donor age ≥ 50 y 1.35 1.05-1.74 .020 0.90 0.65-1.24 .51 
Patient sex, male 1.23 1.00-1.51 .050 0.96 0.75-1.24 .78 
Donor sex, male 0.99 0.77-1.27 .92 1.29 0.89-1.69 .21 
Female donor/male recipient 1.01 0.74-1.38 .96 1.30 0.87-1.95 .20 
Recipient/donor CMV serology†       
 Positive/positive 0.93 0.73-1.19 .56 0.93 0.66-1.31 .67 
 Positive/negative 0.97 0.78-1.22 .83 0.79 0.57-1.08 .14 
 Negative/positive 1.15 0.84-1.56 .39 0.68 0.43-1.08 .10 
Disease risk (high) 1.53 1.30-1.81 <.001 0.78 0.63-0.97 .022 
PS (poor) 1.78 1.41-2.25 <.001 0.70 0.52-0.96 .028 
Stem cell source‡       
 PBSC 1.26 0.92-1.72 .15 1.18 0.78-1.78 .43 
 CB 0.76 0.60-0.98 .035 0.85 0.62-1.16 .30 
Transplant from unrelated donor 1.49 1.08-2.06 .016 0.98 0.64-1.48 .91 
HLA disparity (mismatch) 1.87 1.56-2.25 <.001 0.74 0.59-0.94 .013 
Conditioning (reduced intensity) 1.04 0.86-1.24 .70 0.98 0.78-1.22 .83 
TBI 0.93 0.78-1.10 .40 1.17 0.94-1.46 .15 
GVHD prophylaxis       
 Tacrolimus-based regimen§ 1.07 0.87-1.30 .52 0.83 0.65-1.07 .15 
 Mycophenolate mofetil use 1.21 0.95-1.54 .13 1.15 0.84-1.56 .38 
 TCD in vivo 0.69 0.50-0.97 .032 1.36 0.92-2.01 .13 
Transplant year (2004-2010) 1.05 0.89-1.23 .55 1.04 0.85-1.27 .69 
VariablesBaselineInteraction term
HR95% CIPHR95% CIP
CMV reactivation 1.92 1.05-3.50 .035    
Underlying disease*       
 Acute lymphoblastic leukemia 1.09 0.89-1.32 .41 1.15 0.89-1.47 .29 
 Myelodysplastic syndromes 1.05 0.86-1.29 .64 1.13 0.87-1.46 .36 
 CML 0.74 0.48-1.14 .17 1.76 1.05-2.96 .033 
Patient age ≥ 50 y 1.51 1.26-1.80 <.001 1.11 0.89-1.40 .35 
Donor age ≥ 50 y 1.35 1.05-1.74 .020 0.90 0.65-1.24 .51 
Patient sex, male 1.23 1.00-1.51 .050 0.96 0.75-1.24 .78 
Donor sex, male 0.99 0.77-1.27 .92 1.29 0.89-1.69 .21 
Female donor/male recipient 1.01 0.74-1.38 .96 1.30 0.87-1.95 .20 
Recipient/donor CMV serology†       
 Positive/positive 0.93 0.73-1.19 .56 0.93 0.66-1.31 .67 
 Positive/negative 0.97 0.78-1.22 .83 0.79 0.57-1.08 .14 
 Negative/positive 1.15 0.84-1.56 .39 0.68 0.43-1.08 .10 
Disease risk (high) 1.53 1.30-1.81 <.001 0.78 0.63-0.97 .022 
PS (poor) 1.78 1.41-2.25 <.001 0.70 0.52-0.96 .028 
Stem cell source‡       
 PBSC 1.26 0.92-1.72 .15 1.18 0.78-1.78 .43 
 CB 0.76 0.60-0.98 .035 0.85 0.62-1.16 .30 
Transplant from unrelated donor 1.49 1.08-2.06 .016 0.98 0.64-1.48 .91 
HLA disparity (mismatch) 1.87 1.56-2.25 <.001 0.74 0.59-0.94 .013 
Conditioning (reduced intensity) 1.04 0.86-1.24 .70 0.98 0.78-1.22 .83 
TBI 0.93 0.78-1.10 .40 1.17 0.94-1.46 .15 
GVHD prophylaxis       
 Tacrolimus-based regimen§ 1.07 0.87-1.30 .52 0.83 0.65-1.07 .15 
 Mycophenolate mofetil use 1.21 0.95-1.54 .13 1.15 0.84-1.56 .38 
 TCD in vivo 0.69 0.50-0.97 .032 1.36 0.92-2.01 .13 
Transplant year (2004-2010) 1.05 0.89-1.23 .55 1.04 0.85-1.27 .69 
*

Acute myeloid leukemia was treated as reference.

†

Negative/negative CMV serology was treated as reference.

‡

Bone marrow transplantation was treated as reference.

§

Cyclosporine-based regimen was treated as reference.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal